7,417.30

+63.57

+0.86%

51,564.13

+41.07

+0.08%

24,696.19

+381.19

+1.57%

2,753.72

+23.83

+0.87%

4.8510

+0.0140

+0.29%

24.16

-4.02

-14.15%

4,068.60

-44.90

-1.09%

75,759.86

+73.15

+0.10%

Crude Oil Dec 26

90.27

-0.25

-0.28%

US Private Equity

10,760.93

-143.81

-1.32%

Breaking One day after a $2.3T market sell-off, U.S. October jobs report blows past estimates

NasdaqCM - Nasdaq Real Time Price USD

EUDA Health Holdings Limited (EUDA)

14.76 -0.27 (-1.80%)

As of 11:59:09 AM EST. Market Open.

Loading Chart for EUDA

Chart Range Bar

Interval:

In partnership with ChartIQ

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

Top Midday Gainers

Top Midday Gainers

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

EUDA Health price target lowered to $2.75 from $6 at Greenridge

EUDA Health price target lowered to $2.75 from $6 at Greenridge

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital

EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

Mobilize your Website

View Site in Mobile | Classic

Share by: